Companies in the Health Care sector

XLV stock price: $88.76 -2.31% At close on Aug 23rd, 2019

Health Care sector definition

The healthcare sector consists of companies that provide medical services, manufacture medical equipment or drugs, provide medical insurance, or otherwise facilitate the provision of healthcare to patients.

Health Care sector is composed of 853 companies with a total market capitalization of $4.95 tn

Health Care companies

NeoGenomics, Inc. (NEO)

NeoGenomics, Inc., together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States.It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for various stains; and molecular testing services that focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. The company also provides pathology consultation services for clients in which its pathologists review surgical samples on a consultative basis; and testing services in support of its pharmaceutical clients' oncology programs, as well as acts as a reference laboratory supplying anatomic pathology testing services. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

  • Industry: Precision Instruments
  • Country: USA
  • Market cap: $1.64 bn
  • 3M gains: +14.92 %
  • Avg. Volume: 4.7 M

NovoCure Limited (NVCR)

  • Industry: Medical/Dental Instruments
  • Country: USA
  • Market cap: $4.89 bn
  • 3M gains: +74.81 %
  • Avg. Volume: 3.9 M

Novo Nordisk A/S (NVO)

Novo Nordisk A\u002FS, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide.It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides insulins, GLP-1 and related delivery systems, and oral anti-diabetic drugs and obesity. The Biopharmaceuticals segment offers products in the areas of haemophilia care, growth hormone therapy, and hormone replacement therapy. The company markets and distributes its products through distributors and independent agents. Novo Nordisk A\u002FS was founded in 1925 and is headquartered in Bagsvaerd, Denmark.

  • Industry: Major Pharmaceuticals
  • Country: Denmark
  • Market cap: $119.07 bn
  • 3M gains: +8.49 %
  • Avg. Volume: 7.3 M

Novartis AG (NVS)

Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers.This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines. The Sandoz segment provides active ingredients and finished dosage forms of pharmaceuticals in the areas of cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapies, metabolism, oncology, ophthalmic, pain, and respiratory; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. The Alcon segment offers eye care products, such as eye care devices for cataract, retinal, glaucoma, and refractive surgery, as well as intraocular lenses to treat cataracts and refractive errors; viscoelastics, surgical solutions, surgical packs, and other disposable products for cataract and vitreoretinal surgery; and contact lenses, as well as contact lens care products, including multi-purpose and hydrogen-peroxide based solutions, rewetting drops, and daily protein removers. Novartis AG has collaboration agreements with Xencor; Surface Oncology; Intellia Therapeutics; Caribou Biosciences; Bristol-Myers Squibb; IBM Watson Health; Amgen; Allergan plc; and Bill & Melinda Gates Foundation. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.

  • Industry: Major Pharmaceuticals
  • Country: Switzerland
  • Market cap: $205.74 bn
  • 3M gains: +1.05 %
  • Avg. Volume: 10.1 M

Seattle Genetics, Inc. (SGEN)

Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of targeted therapies for the treatment of cancer worldwide.It markets ADCETRIS, an antibody-drug conjugate for the treatment of relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. The company also develops enfortumab vedotin, which is in Phase 1 clinical trial for Nectin-4-positive solid tumors, including bladder cancer; and tisotumab vedotin that is in Phase II clinical trial for patients with cervical cancer and solid tumors. In addition, it conducts phase 3 clinical trials of ADCETRIS which includes ECHELON-1 for patients with newly diagnosed advanced stage classical Hodgkin lymphoma; ECHELON-2 for patients with newly diagnosed CD30-expressing MTCL; and the CHECKMATE 812 for patients with relapsed or refractory or transplant-ineligible, and advanced classical Hodgkin lymphoma. Further, the company's earlier stage clinical pipeline includes six other ADC programs consisting of ladiratuzumab vedotin, denintuzumab mafodotin, SGN-CD19B, SGN-CD123A, SGN-CD33A, and SGN-CD352A, as well as two immuno-oncology agents, including SEA-CD40 and SGN-2FF. It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc., PSMA Development Company LLC; Takeda Pharmaceutical Company Limited, Unum Therapeutics, Inc., and Genmab A\u002FS, as well as has co-development agreement with Agensys, Inc. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.

  • Industry: Biotechnology
  • Country: USA
  • Market cap: $11.01 bn
  • 3M gains: +10.34 %
  • Avg. Volume: 4.6 M

Shire plc (SHPG)

Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells specialist medicines for people with rare diseases and other specialized conditions worldwide.The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE\u002FADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. The company's marketed products also comprise VYVANSE\u002FVENVANSE\u002FELVANSE\u002FTYVENSE\u002FVUXEN\u002FADUVANZ for the treatment of attention deficit\u002Fhyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR and MYDAYIS to treat ADHD; GAMMAGARD LIQUID\u002FKIOVIG, GAMMAGARD S\u002FD, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of CINRYZE and FIRAZYR for the treatment of hereditary angioedema; FOSRENOL to treat hyperphosphatemia; LIALDA\u002FMEZAVANT and PENTASA for ulcerative colitis; GATTEX\u002FREVESTIVE for the treatment of short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA for the treatment of dry eye disease. The company markets its products through wholesalers, distributors, and pharmacies. It has collaborative and other licensing arrangements with Rani Therapeutics LLC; Parion Sciences Inc.; Pfizer Inc.; Precision BioSciences Inc.; Symphogen; and Ipsen Bioscience Inc. The company was founded in 1986 and is headquartered in Dublin, Ireland.

  • Industry: Major Pharmaceuticals
  • Country: Ireland
  • Market cap: $12.11 bn
  • 3M gains: -1.14 %
  • Avg. Volume: 6.4 M

Sanofi (SNY)

Sanofi researches, develops, manufactures, and markets therapeutic solutions. The company operates in two segments, Pharmaceuticals and Vaccines.It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an oral immunomodulatory and Lemtrada, a monoclonal antibody to treat multiple sclerosis. The company also provides Jevtana, a taxane derivative for prostate cancer; Taxotere, a taxoid for various cancers; Eloxatin, a platinum agent for colorectal cancer; Thymoglobulin, a immunosuppressive and immunomodulating agent; Mozobil, a hematopoietic stem cell mobilizer for hematologic malignancies; and Zaltrap, a protein for metastatic colorectal cancer. In addition, it offers Lantus, Apidra, and Insuman human insulins; Toujeo, an oral sulfonylurea; Lyxumia\u002FAdlyxin, a GLP-1 receptor agonist; and Soliqua 100\u002F33\u002FSuliqua, an insulin glargine and lixisenatide combination to treat diabetes; and Praluent, a cholesterol-lowering drug and Multaq, an anti-arrhythmic drug to treat cardiovascular diseases. Further, the company provides Plavix, an anti-platelet agent for atherothrombotic conditions; Lovenox, a heparin for the prophylaxis and treatment of venous thromboembolism and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela oral phosphate binders for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for patients with osteoarthritis; Stilnox for treatment of insomnia; and Allegra, an anti-histamine for the treatment of seasonal allergic rhinitis and uncomplicated hives. Additionally, it offers consumer health care products and generic medicines; and pediatric, influenza, adult and adolescent booster, meningitis, and travel and endemic vaccines. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

  • Industry: Major Pharmaceuticals
  • Country: France
  • Market cap: $9.03 bn
  • 3M gains: +0.71 %
  • Avg. Volume: 7.4 M

Stryker Corporation (SYK)

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine.The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products that include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. It also provides spinal implant products comprising cervical, thoracolumbar, and interbody systems for use in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned sales subsidiaries and branches, as well as third-party dealers and distributors in approximately 85 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.

  • Industry: Medical/Dental Instruments
  • Country: USA
  • Market cap: $69.14 bn
  • 3M gains: +16.17 %
  • Avg. Volume: 5.0 M

TESARO, Inc. (TSRO)

Tesaro, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States.It markets Rolapitant, a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting under the VARUBI brand name. The company is also developing Niraparib, an orally active and potent poly polymerase inhibitor, which is in various clinical trials to treat ovarian or breast cancers. In addition, it is developing immunotherapy antibody product candidates, including TSR-042, which is in a phase I clinical trial targeting programmed cell death protein 1; TSR-022 that is in phase I clinical trial targeting T-cell immunoglobulin domain and mucin domain-3; and TSR-033, an antibody candidate, which is in pre-clinical research stage targeting lymphocyte-activation gene-3. It has license and collaboration agreements with AnaptysBio, Inc.; and The University of Texas MD Anderson Cancer Center, as well as with Janssen Biotech, Inc., Zai Lab (Shanghai) Co., Ltd, OPKO Health, Inc. The company also has collaboration agreements with Evotec AG and OncoQuest Inc. Tesaro, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

  • Industry: Major Pharmaceuticals
  • Country: USA
  • Market cap: $1.92 bn
  • 3M gains: +79.54 %
  • Avg. Volume: 18.0 M

Universal Health Services, Inc. (UHS)

Universal Health Services, Inc., through its subsidiaries, owns and operates acute care hospitals, behavioral health facilities, and ambulatory centers.The company's hospitals offer general and specialty surgery, internal medicine, obstetrics, emergency room care, radiology, oncology, diagnostic care, coronary care, pediatric services, pharmacy services, and\u002For behavioral health services. As of February 28, 2017, it owned and\u002For operated 26 inpatient acute care hospitals, 4 free-standing emergency departments, 1 surgical hospital, and 319 inpatient and 33 outpatient behavioral health care facilities located in 37 states, Washington, D.C.; the United Kingdom; Puerto Rico; and the U.S. Virgin Islands. The company was founded in 1978 and is headquartered in King of Prussia, Pennsylvania.

  • Industry: Hospital/Nursing Management
  • Country: USA
  • Market cap: $12.37 bn
  • 3M gains: +16.66 %
  • Avg. Volume: 3.1 M

Vertex Pharmaceuticals Incorporated (VRTX)

Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs.It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for the treatment of patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor\u002Fivacaftor. The company also develops VX-659 and VX-445, which are CFTR corrector compounds in Phase II clinical trial; VX-150 that is in Phase II clinical trial to treat pain; VX-128, which is in Phase I clinical trial for the treatment of pain; CTX001, an investigational gene editing treatment that is in Phase I\u002FII trial for the treatment of beta-thalassemia and sickle cell disease; pimodivir (JNJ-63623872), which is in a Phase III clinical development program to treat influenza; and VX-210 to treat acute spinal cord injury. It sells its products primarily to specialty pharmacy providers in North America, as well as government-owned and supported customers internationally. The company has collaborations with Cystic Fibrosis Foundation Therapeutics Incorporated; CRISPR Therapeutics AG; Moderna Therapeutics, Inc.; BioAxone Biosciences, Inc.; Parion Sciences, Inc.; Merck KGaA; and Janssen Pharmaceuticals, Inc. The company was founded in 1989 and is headquartered in Boston, Massachusetts.

  • Industry: Major Pharmaceuticals
  • Country: USA
  • Market cap: $47.46 bn
  • 3M gains: +4.90 %
  • Avg. Volume: 5.7 M

Zimmer Biomet Holdings, Inc. (ZBH)

Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.It operates through four segments: Americas Spine, Office Based Technologies, Craniomaxillofacial and Thoracic (CMF), and Dental. The company provides orthopedic reconstructive products, such as knee and hip reconstructive products; S.E.T. products, including surgical, sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products; and bone cement and spinal fusion stimulators. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopaedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

  • Industry: Industrial Specialties
  • Country: USA
  • Market cap: $24.99 bn
  • 3M gains: +16.94 %
  • Avg. Volume: 5.9 M

Abbott Laboratories (ABT)

  • Industry: Major Pharmaceuticals
  • Country:
  • Market cap: $129.92 bn
  • 3M gains: +6.83 %
  • Avg. Volume: 24.6 M

Achillion Pharmaceuticals, Inc. (ACHN)

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for infectious diseases and immune system disorders in the United States and internationally.Its drug candidates for treating chronic hepatitis C virus (HCV) infection comprise Odalasvir, a NS5A inhibitor, which has completed Phase IIa clinical trials; ACH-3422, a NS5B nucleotide polymerase inhibitor; and Sovaprevir, a NS3 protease inhibitor that has completed Phase II clinical trial. The company is also developing ACH-4471, a complement factor D inhibitor, which is in Phase I clinical trial to treat patients with paroxysmal nocturnal hemoglobinuria and C3G, a disease resulting from alternative pathway over-activation; and other factor D inhibitors. It has a license and development agreement with Ora, Inc. for the development and commercialization of ACH-702, a drug candidate that is delivered topically or locally; and collaboration arrangement with Janssen Pharmaceuticals Inc. to develop and commercialize antiviral drug candidates for treating HCV infection. The company was founded in 1998 and is headquartered in New Haven, Connecticut.

  • Industry: Major Pharmaceuticals
  • Country: USA
  • Market cap: $325.74 M
  • 3M gains: +50.00 %
  • Avg. Volume: 7.6 M

Acasti Pharma, Inc. (ACST)

Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases.The company's lead product candidate is CaPre, an omega-3 phospholipid for the treatment of hypertriglyceridemia. Acasti Pharma Inc. was incorporated in 2002 and is based in Laval, Canada.

  • Industry: Major Pharmaceuticals
  • Country: Canada
  • Market cap: $72.19 M
  • 3M gains: +107.95 %
  • Avg. Volume: 9.6 M

Allergan plc. (AGN)

Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide.It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer's disease. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. In addition, the company distributes generic and branded pharmaceutical products primarily to independent and chain pharmacies, nursing homes, mail order pharmacies, hospitals, clinics, and physician offices. Further, it develops a portfolio of breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. The company has licensing agreement with Assembly Biosciences, Inc.; Mimetogen Pharmaceuticals, Inc.; Almirall, S.A; Naurex, Inc.; and Merck & Co. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.

  • Industry: Major Pharmaceuticals
  • Country: USA
  • Market cap: $46.77 bn
  • 3M gains: +17.85 %
  • Avg. Volume: 23.2 M

Allakos Inc. (ALLK)

  • Industry: Major Pharmaceuticals
  • Country:
  • Market cap: $1.48 bn
  • 3M gains: +95.15 %
  • Avg. Volume: 3.2 M

Cambrex Corporation (CBM)

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide.Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals. The company serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey.

  • Industry: Major Pharmaceuticals
  • Country: USA
  • Market cap: $1.2 bn
  • 3M gains: +42.21 %
  • Avg. Volume: 2.6 M

Catalyst Pharmaceuticals, Inc. (CPRX)

Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies for people with rare debilitating diseases.Its lead product candidate is Firdapse, a proprietary form of amifampridine phosphate, which is in second Phase III clinical trials for the treatment of patients with Lambert-Eaton Myasthenic syndrome; and is in small blinded clinical trial to treat Congenital Myasthenic syndromes, as well as is in Phase II\u002FIII clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis. The company also develops CPP-115, a gamma-aminobutyric acid aminotransferase inhibitor that is in Phase Ib clinical trial for the treatment of epilepsy, infantile spams, and Tourette's disorder; and CPP-109 to treat Tourette's disorder. It has a strategic collaboration with BioMarin Pharmaceutical Inc. for the development of Firdapse. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

  • Industry: Major Pharmaceuticals
  • Country: USA
  • Market cap: $278.42 M
  • 3M gains: +65.93 %
  • Avg. Volume: 7.1 M

CVS Health Corporation (CVS)

CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail\u002FLTC segments.The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services. This segment serves employers, insurance companies, unions, government employee groups, health plans, Medicare Part D plans, managed Medicaid plans, plans offered on public and private exchanges, other sponsors of health benefit plans, and individuals under the CVS Caremark Pharmacy Services, Caremark, CVS Specialty, AccordantCare, SilverScript, Wellpartner, NovoLogix, Coram, Navarro Health Services, and ACS Pharmacy names. As of December 31, 2017, it had 23 retail specialty pharmacy stores, 18 specialty mail order pharmacies and 4 mail order dispensing pharmacies, and 83 branches for infusion and enteral services. The Retail\u002FLTC segment sells prescription drugs, over-the-counter drugs, beauty products and cosmetics, personal care products, convenience foods, seasonal merchandise, and greeting cards, as well as offers photo finishing services. It has 9,803 retail stores in 49 states, the District of Columbia, Puerto Rico, and Brazil primarily under the CVS Pharmacy, CVS, CVS Pharmacy y más, Longs Drugs, Navarro Discount Pharmacy, and Drogaria Onofre names; online retail pharmacy Websites; and 37 onsite pharmacy stores, long-term care pharmacy operations, and retail health care clinics. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was founded in 1892 and is headquartered in Woonsocket, Rhode Island.

  • Industry: Medical/Nursing Services
  • Country: USA
  • Market cap: $87.54 bn
  • 3M gains: +14.52 %
  • Avg. Volume: 41.2 M

Health Care sector performance

Healthcare sector ETF ended this week at $88.76 and slightly fell a fatal -1.98%.

XLV marked an uptrend of rising tops and rising bottoms. Since its last top early July at $94.42, price slid and bounced up back from $88.19. Breaking down under $88.19 would cancel the current uptrend and it might test lower supports. Note that $94.42 might act as a resistance line. This week, Healthcare sector ETF stock dived below the significant level of the 40-weeks moving average. Trading stocks that are below the 40-weeks (that is, 200-days) moving average line is not recommended by many experts, as it indicates that the stock has not enough institutional support. Since late May when SMA20w and SMA40w crossed up, XLV price slipped $-0.42 per share (-0.47%). Far behind is the all-time high Healthcare sector ETF marked early October but price is just -6.44% below that top.

Healthcare sector ETF performance
3 months-0.47 %
6 months-3.32 %
1 year-1.81 %

Health Care sector industries

Industry
Biotechnology
Hospital/Nursing Management
Industrial Specialties
Major Pharmaceuticals
Medical Electronics
Medical Specialities
Medical/Dental Instruments
Medical/Nursing Services
Ophthalmic Goods
Other Pharmaceuticals
Precision Instruments

Top performing stocks in the Health Care sector

Company3M gain6M gain
Aetna+6.21 %+20.44 %
Astrazeneca+15.43 %+12.55 %
Baxter International+13.54 %+14.47 %
Merck+5.41 %+6.65 %